Charles Carter was named Chief Financial Officer of Ovid Therapeutics Inc. As of November 6, 2026, Ovid Therapeutics Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from June 3, 2026 to July 8, 2026, naming 1 appointment (Form 8-K, July 8, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Ovid Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Ovid Therapeutics Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-06-03 to 2026-07-08. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Ovid Therapeutics Inc. files it.
Also on the record for Ovid Therapeutics Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G/A, by ADAR1 Capital Management, LLC | 5.1% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by BALYASNY ASSET MANAGEMENT L.P. | 4.99% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Eventide Asset Management, LLC | 6.3% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by RA Capital Management, L.P. | 9.9% of the class | 5%+ stakes | Source |
| August 13, 2026 | Stake report, Schedule 13G/A, by Affinity Asset Advisors, LLC | 7.9% of the class | 5%+ stakes | Source |
| July 29, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 5.8% of the class | 5%+ stakes | Source |
| July 8, 2026 | Stake report, Schedule 13G/A, by Federated Hermes, Inc. | 4.15% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Balyasny Asset Management L.P. | 5.33% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Eventide Asset Management, LLC | 7.3% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Sirenia Capital Management LP | 9.9% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Point72 Asset Management, L.P. | 1.3% of the class | 5%+ stakes | Source |
| May 14, 2026 | Stake report, Schedule 13G/A, by Affinity Asset Advisors, LLC | 9.1% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Ovid Therapeutics Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Ovid Therapeutics Inc. and the records around it.
Ovid Therapeutics Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- Eventide Asset Management, LLC also filed stake reports on 9 other companies: Immix Biopharma, Inc. (Aug 2026), Beta Bionics, Inc. (May 2026), COLLEGIUM PHARMACEUTICAL, INC (May 2026)
- Affinity Asset Advisors, LLC also filed stake reports on 13 other companies: Amanat Acquisition Corp. (Aug 2026), Avalo Therapeutics, Inc. (Aug 2026), Equillium Inc. (Aug 2026)
- Federated Hermes, Inc. also filed stake reports on 13 other companies: EyePoint (Nov 2026), Arcturus Therapeutics Holdings Inc. (Oct 2026), Forte Biosciences, Inc. (Sep 2026)
Watch Ovid Therapeutics Inc.
Get an email when Ovid Therapeutics Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Ovid Therapeutics Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Ovid Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Ovid Therapeutics Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 24 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-07-08 | In | Chief Financial Officer | 8-K, 2026-07-08 | ||
| 2026-06-03 | Reported | not named in the filing | 8-K, 2026-06-03 |
Who leads Ovid Therapeutics Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: Charles Carter, appointed (filed 2026-07-08).
New leaders reset buying decisions — get the Full Report on Ovid Therapeutics Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at Ovid Therapeutics Inc., with the record behind each one.
Find candidates like Chief Financial Officer at Ovid Therapeutics Inc.Every change, in the filing's words
Appointed: Charles Carter, Chief Financial Officer
In connection with Mr. Rona's departure, the Company's Board of Directors (the "Board") appointed Charles Carter, the Company's Senior Vice President of Finance and Financial Planning, as the Company's Chief Financial Officer, principal financial officer, principal accounting officer and secretary, effective as of the Separation Date.
- Executive Transition On July 5, 2026, Ovid Therapeutics Inc. (the "Company") and Jeffrey Rona, who served as the Company's Chief Business and Financial Officer, principal financial officer, principal accounting officer and secretary, mutually agreed to Mr. Rona's transition from such roles with the Company, effective July 6, 2026 (the "Separation Date").
- Mr. Rona's departure was not the result of any disagreement with the Company on any matter relating to the Company's accounting practices, financial statements, internal controls over financial reporting, operations, policies or practices.
- Mr. Carter, age 59, served as the Company's Senior Vice President of Finance and Financial Planning from October 2024 to July 2026.
- From February 2024 to September 2024, he was the Chief Financial Officer and Corporate Secretary of CERo Therapeutics Holdings, Inc. (Nasdaq: CERO), a cellular immunotherapy company ("CERo"), during which time he prepared the company for a complex de-SPAC transaction and helped launch CERo as a public company.
- Prior to that, Mr. Carter was Senior Director at Danforth Advisors, LLC, a strategic consulting firm for life sciences companies (from June 2022 to February 2024), during which time he headed the finance and accounting functions for multiple biotech companies.
Reported
On May 29, 2026, the Board of Directors (the "Board") of Ovid Therapeutics Inc. (the "Company") approved, effective as of June 15, 2026, an increase in the size of the Board and, upon recommendation of the Nominating and Corporate Governance Committee of the Board (the "Nominating Committee"), the appointment of Anna Greka, M.D., Ph.D., as a Class III director of the Company, with her term expiring at the Company's 2029 annual meeting of stockholders.
- Effective as of June 15, 2026, the Board will consist of seven directors.
- Dr. Greka was appointed as a member of the Compensation Committee and Science and Technology Committee of the Board, effective as of June 15, 2026.
- Dr. Greka, age 50, currently serves as Professor of Medicine at Harvard Medical School and Mass General Brigham.
- She joined Harvard Medical School as an Assistant Professor in 2012, and has since served in roles of increasing responsibility.
- Dr. Greka also currently holds several roles at the Broad Institute of MIT and Harvard, including Executive Leadership Team Member (since April 2024), Founding Director and Chair of Ladders to Cures Scientific Accelerator (since July 2023), Founding Director of Kidney Disease Initiative (since February 2016) and Core / Institute Faculty Member (since February 2016).
- Additionally, Dr. Greka has served as a Venture Advisor to Aditum Bio, a biotech focused venture capital firm, since 2013, founded and served as an Advisor to Goldfinch Bio, a clinical-stage biotech company, from 2015 to 2023 and founded and advised numerous other biopharmaceutical companies.
- Dr. Greka received her M.D. from the Harvard-MIT program in Health Sciences and Technology, Ph.D. from Harvard Medical School and A.B. from Harvard University.
- The Company and Dr. Greka also entered into the Company's standard form of indemnification agreement.
Tools for this story
Each opens in a new tab, filled in for Ovid Therapeutics Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.